A new dietary strategy for long-term treatment of the metabolic syndrome is compared with the American Heart Association (AHA) guidelines: the MEtabolic Syndrome REduction in NAvarra (RESMENA) project.
Study Goal
The researchers aimed to evaluate the effectiveness of the RESMENA diet, which includes considerations of macronutrient distribution and antioxidant capacity, in reducing metabolic syndrome markers, including alanine aminotransferase levels.
Results Summary
The RESMENA group showed a significant decrease in alanine aminotransferase concentrations (-26.8%; P=0.008), indicating improved liver function, while the Control group did not show similar improvements.
Population
52 men and 41 women with metabolic syndrome, average age 49 years, average BMI 36.11 kg/m².
Effective Dosage
Not specified
Duration
2-month intervention period followed by a 4-month self-control period.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
RESMENA diet | decrease | body weight | Subjects with the metabolic syndrome | -1.7% | exhibited a significant decrease | #1 |
RESMENA diet | decrease | BMI | Subjects with the metabolic syndrome | -1.7% | exhibited a significant decrease | #2 |
RESMENA diet | decrease | waist circumference | Subjects with the metabolic syndrome | -1.8% | exhibited a significant decrease | #3 |
RESMENA diet | decrease | waist:hip ratio | Subjects with the metabolic syndrome | -1.4% | exhibited a significant decrease | #4 |
RESMENA diet | decrease | android fat mass | Subjects with the metabolic syndrome | -6.9% | exhibited a significant decrease | #5 |
RESMENA diet | decrease | alanine aminotransferase concentrations | Subjects with the metabolic syndrome | -26.8% | exhibited a significant decrease | #6 |
RESMENA diet | decrease | aspartate aminotransferase (AST) concentrations | Subjects with the metabolic syndrome | -14.0% | exhibited a significant decrease | #7 |
American Heart Association guidelines (Control diet) | increase | glucose concentrations | Subjects with the metabolic syndrome | 7.9% | exhibited a significant increase | #8 |
American Heart Association guidelines (Control diet) | increase | aspartate aminotransferase (AST) concentrations | Subjects with the metabolic syndrome | 11.3% | exhibited a significant increase | #9 |
American Heart Association guidelines (Control diet) | increase | uric acid concentrations | Subjects with the metabolic syndrome | 9.0% | exhibited a significant increase | #10 |
American Heart Association guidelines (Control diet) | increase | LDL-cholesterol (LDL-C) concentrations | Subjects with the metabolic syndrome | 34.4% | were increased | #11 |
RESMENA diet | increase | LDL-cholesterol (LDL-C) concentrations | Subjects with the metabolic syndrome | 33.8% | were increased | #12 |
American Heart Association guidelines (Control diet) | increase | LDL-C:apoB ratio | Subjects with the metabolic syndrome | 28.7% | were increased | #13 |
RESMENA diet | increase | LDL-C:apoB ratio | Subjects with the metabolic syndrome | 17.1% | were increased | #14 |
American Heart Association guidelines (Control diet) | increase | HDL-cholesterol concentrations | Subjects with the metabolic syndrome | 21.1% | were increased | #15 |
RESMENA diet | increase | HDL-cholesterol concentrations | Subjects with the metabolic syndrome | 8.7% | were increased | #16 |
Fibre | neutral | anthropometry | Subjects with the metabolic syndrome | - | most contributed to the improvement | #17 |
body-weight loss | neutral | some biochemical markers | Subjects with the metabolic syndrome | - | explained changes | #18 |
The long-term effects of dietary strategies designed to combat the metabolic syndrome (MetS) remain unknown. The present study evaluated the effectiveness of a new dietary strategy based on macronutrient distribution, antioxidant capacity and meal frequency (MEtabolic Syndrome REduction in NAvarra (RESMENA) diet) for the treatment of the MetS when compared with the American Heart Association guidelines, used as Control. Subjects with the MetS (fifty-two men and forty-one women, age 49 (se 1) years, BMI 36·11 (se 0·5) kg/m²) were randomly assigned to one of two dietary groups. After a 2-month nutritional-learning intervention period, during which a nutritional assessment was made for the participants every 15 d, a 4-month self-control period began. No significant differences were found between the groups concerning anthropometry, but only the RESMENA group exhibited a significant decrease in body weight ( - 1·7%; P= 0·018), BMI ( - 1·7%; P= 0·019), waist circumference ( - 1·8%; P= 0·021), waist:hip ratio ( - 1·4%; P= 0·035) and android fat mass ( - 6·9%; P= 0·008). The RESMENA group exhibited a significant decrease in alanine aminotransferase and aspartate aminotransferase (AST) concentrations ( - 26·8%; P= 0·008 and - 14·0%; P= 0·018, respectively), while the Control group exhibited a significant increase in glucose (7·9%; P= 0·011), AST (11·3%; P= 0·045) and uric acid (9·0%; P< 0·001) concentrations. LDL-cholesterol (LDL-C) concentrations were increased (Control group: 34·4%; P< 0·001 and RESMENA group: 33·8%; P< 0·001), but interestingly so were the LDL-C:apoB ratio (Control group: 28·7%; P< 0·001, RESMENA group: 17·1%; P= 0·009) and HDL-cholesterol concentrations (Control group: 21·1%; P< 0·001, RESMENA group: 8·7; P= 0·001). Fibre was the dietary component that most contributed to the improvement of anthropometry, while body-weight loss explained changes in some biochemical markers. In conclusion, the RESMENA diet is a good long-term dietary treatment for the MetS.